CORT For The Long Haul, RVNC Has No Reason To Frown, MSLI Swings To Profit

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) has acquired rights to Testosterone Gel 1% product, previously licensed to Teva Pharmaceutical Industries Ltd. (TEVA).

Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.

ANIP closed Wednesday's trading at $51.31, down 1.69%.

Corcept Therapeutics Inc.'s (CORT) multi-center phase 1/2 dose-escalation study of investigational drug Imifepristone combined with Eisai Co's approved chemotherapy drug Halaven has shown that the combination is well tolerated and clinically active in patients with triple-negative breast cancer.

The above findings were from the first phase of the study, which enrolled 13 metastatic breast cancer patients, to determine the maximum tolerated dose of the Mifepristone-Halaven combination. An additional 20 patients with GR(glucocorticoid receptors)-positive metastatic triple-negative breast cancer will be enrolled into the study's efficacy phase.

The company noted that if the phase 1/2 demonstrates efficacy, it will begin a phase 3 study in early 2016.

CORT closed Wednesday's trading at $5.67, down 0.70%.

Dicerna Pharmaceuticals Inc. (DRNA) is scheduled to present new clinical data from a phase I study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma on June 1, 2015 at the 2015 American Society of Clinical Oncology Annual Meeting.

DRNA closed Wednesday's trading at $21.59, up 5.32%.

Merus Labs International Inc. (MSLI) swung to profit in the second quarter ended March 31, 2015 as revenues surged nearly 90% over the year-ago period.

The company earned a net income of $2.16 million on revenue of $12.70 million in Q2, 2015. This compares with a net loss of $1.45 million and revenue of $6.69 million in Q2, 2014.

MSLI closed Wednesday's trading at $2.42, down 1.63%.

Pieris Pharmaceuticals Inc. (PIRS.OB), which has been progressing on its phase I clinical trial for PRS-080, an anti-hepcidin Anticalin therapeutic protein designed to treat anemia, expects to report results in second half of this year.

PIRS.OB closed Wednesday's trading 7.50% higher at $3.01.

Proteon Therapeutics Inc. (PRTO) expects its first phase III clinical trial evaluating Vonapanitase in patients with chronic kidney disease undergoing surgical creation of an arteriovenous fistula for hemodialysis to be fully enrolled by the end of 2015. Data from this trial are anticipated to be available in the first quarter of 2017.

The company expects to enroll the first patient in its second phase III clinical trial of Vonapanitase during this quarter.

Proteon went public on the NASDAQ Global Market on October 22, 2014, priced at $10.00 per share.

PRTO closed Wednesday's trading at $16.00, down 3.73%.

Revance Therapeutics Inc. (RVNC) expects results from a phase II study evaluating its injectable botulinum toxin product candidate RT002 against the market leader for the treatment of frown lines to be available later this year. The study, dubbed BELMONT, has completed enrollment.

The company also plans to commence a phase II clinical trial of RT002 in cervical dystonia in the second half of 2015 and report preliminary efficacy results before year end.

Another investigational product of the company is RT001, a topically-applied form of botulinum toxin type A.

Revance is planning to initiate a phase III pivotal trial of RT001 for crow's feet lines this summer and report preliminary efficacy results before the end of the year. A phase II study of RT001 for the treatment of hyperhidrosis, or excessive sweating is expected to be initiated mid-year - with preliminary efficacy results scheduled in the second half of 2015.

RVNC closed Wednesday's trading 0.25% higher at $20.29.